TRCT
TERN

Tower Research Capital (TRC)’s Terns Pharmaceuticals TERN Stock Holding History

Tower Research Capital (TRC)’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Buy
7,455
+5,844
+363% +$240K 0.01% 1099
2025
Q4 		$65.1K Sell
1,611
-701
-30% -$16.2K ﹤0.01% 2234
2025
Q3 		$17.4K Sell
2,312
-5,885
-72% -$37.6K ﹤0.01% 3431
2025
Q2 		$30.6K Buy
8,197
+1,274
+18% +$3.98K ﹤0.01% 3384
2025
Q1 		$19.1K Buy
6,923
+3,512
+103% +$14.3K ﹤0.01% 3016
2024
Q4 		$18.9K Sell
3,411
-2,706
-44% -$18.3K ﹤0.01% 3229
2024
Q3 		$51K Sell
6,117
-2,608
-30% -$21.5K ﹤0.01% 2709
2024
Q2 		$59.4K Buy
8,725
+8,106
+1,310% +$49.1K ﹤0.01% 2963
2024
Q1 		$4.06K Sell
619
-22,377
-97% -$146K ﹤0.01% 4745
2023
Q4 		$149K Buy
22,996
+21,942
+2,082% +$116K ﹤0.01% 2322
2023
Q3 		$5.3K Sell
1,054
-6,957
-87% -$44.1K ﹤0.01% 4738
2023
Q2 		$70.1K Buy
8,011
+4,361
+119% +$50.8K ﹤0.01% 2306
2023
Q1 		$43K Sell
3,650
-1,889
-34% -$18.1K ﹤0.01% 2642
2022
Q4 		$57K Sell
5,539
-1,062
-16% -$7.07K ﹤0.01% 2260
2022
Q3 		$39K Sell
6,601
-3,879
-37% -$14.4K ﹤0.01% 3387
2022
Q2 		$26K Buy
10,480
+6,924
+195% +$13.8K ﹤0.01% 3521
2022
Q1 		$11K Buy
3,556
+2,013
+130% +$8.59K ﹤0.01% 4216
2021
Q4 		$11K Buy
1,543
+784
+103% +$6.53K ﹤0.01% 4457
2021
Q3 		$8K Sell
759
-421
-36% -$4.37K ﹤0.01% 4569
2021
Q2 		$14K Buy
1,180
+566
+92% +$9.64K ﹤0.01% 4190
2021
Q1 		$14K Buy
+614
New +$13.5K ﹤0.01% 4168

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Tower Research Capital (TRC)'s TERN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Terns Pharmaceuticals (TERN) stake by 363% in Q1 2026, buying an estimated $240K and bringing the position to 7,455 shares worth $393K. The position accounts for 0.01% of the portfolio, ranked #1099.

Tower Research Capital (TRC) first reported a position in TERN in Q1 2021 and has held it in 21 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Tower Research Capital (TRC) held 7,455 shares of Terns Pharmaceuticals worth $393K as of Q1 2026.
  • Tower Research Capital (TRC) bought 5,844 Terns Pharmaceuticals shares in Q1 2026, an estimated $240K.
  • Terns Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1099 holding.
  • Tower Research Capital (TRC) first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.